Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).
Valeria DipasqualeSalvatore PellegrinoMarco VentimigliaMichele CitranoFrancesco GrazianoMaria CappelloAnita BusaccaAmbrogio OrlandoSalvatore AccomandoClaudio Romanonull Sicilian Network For Inflammatory Bowel DiseasePublished in: Healthcare (Basel, Switzerland) (2024)
This is the first real-world study that particularly addresses the use of ADL-BioS in pediatric IBD. With high rates of treatment persistence and a low frequency of non-serious side effects, ADL-BioS seems to be effective.